236 related articles for article (PubMed ID: 30268633)
1. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract][Full Text] [Related]
2. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
3. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
[TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
5. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
6. Current and future role of genetic screening in gynecologic malignancies.
Ring KL; Garcia C; Thomas MH; Modesitt SC
Am J Obstet Gynecol; 2017 Nov; 217(5):512-521. PubMed ID: 28411145
[TBL] [Abstract][Full Text] [Related]
7. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
[TBL] [Abstract][Full Text] [Related]
8. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Angeli D; Salvi S; Tedaldi G
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046255
[TBL] [Abstract][Full Text] [Related]
9. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
[TBL] [Abstract][Full Text] [Related]
10. Cascade screening in HBOC and Lynch syndrome: guidelines and procedures in a UK centre.
Evans DG; Green K; Burghel GJ; Forde C; Lalloo F; Schlecht H; Woodward ER
Fam Cancer; 2024 Jun; 23(2):187-195. PubMed ID: 38478259
[TBL] [Abstract][Full Text] [Related]
11. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
[TBL] [Abstract][Full Text] [Related]
12. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
[TBL] [Abstract][Full Text] [Related]
13. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
14. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Kleibl Z; Kristensen VN
Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
[TBL] [Abstract][Full Text] [Related]
15. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
16. The use of panel testing in familial breast and ovarian cancer.
Prapa M; Solomons J; Tischkowitz M
Clin Med (Lond); 2017 Dec; 17(6):568-572. PubMed ID: 29196360
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
[TBL] [Abstract][Full Text] [Related]
18. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
19. Genetic characterization of early onset ovarian carcinoma.
Bernards SS; Norquist BM; Harrell MI; Agnew KJ; Lee MK; Walsh T; Swisher EM
Gynecol Oncol; 2016 Feb; 140(2):221-5. PubMed ID: 26718727
[TBL] [Abstract][Full Text] [Related]
20. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.
Malander S; Rambech E; Kristoffersson U; Halvarsson B; Ridderheim M; Borg A; Nilbert M
Gynecol Oncol; 2006 May; 101(2):238-43. PubMed ID: 16360201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
